Mucopolysaccharidosis Type VI clinical trials at UCLA
1 in progress, 0 open to eligible people
Sorry, in progress, not accepting new patients
Randomized, double-blind, placebo-controlled, parallel-group, single-center study followed by open-label phase, to evaluate the effects of adalimumab compared to placebo on the change from baseline in joint and skeletal disease in children and adults with mucopolysaccharidosis (MPS) I, II or VI.
Our lead scientists for Mucopolysaccharidosis Type VI research studies include Lynda Polgreen, MD.